Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dexamethasone Pill Clear all
Terminated Phase 3 Interventional

Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

NCT01002248
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Perifosine, Perifosine Placebo, Bortezomib, Dexamethasone
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
39
States / cities
La Verne, California • San Francisco, California • San Pablo, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2018 · Synced Oct 21, 2026, 6:29 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women

NCT04037605
View directory record Official record
Conditions
Sleep Restriction
Interventions
Ketoconazole Pill (also known as nizoral), Ganirelix, Dexamethasone Pill, Dexamethasone injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone (also known as luveris), Hydrocortisone Injection (also known as solu-cortef), Gonadorelin (also known as Lutrepulse), Corticorelin (also known as Acthrel), Placebo oral tablet, Saline Solution, Saline solution for injection
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
60 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 21, 2026, 6:29 AM EDT
Not listed Phase 4 Interventional

Ovulation Induction With Clomiphene Citrate and Dexamethasone

NCT01856062
View directory record Official record
Conditions
Infertility
Interventions
Placebo, Dexamethasone
Drug
Lead sponsor
San Antonio Military Medical Center
Federal
Eligibility
18 Years to 40 Years · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2014 · Synced Oct 21, 2026, 6:29 AM EDT
Completed Not applicable Interventional Results available

Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant

NCT00248547
View directory record Official record
Conditions
Cancer
Interventions
aprepitant, dexamethasone, ondansetron, placebo
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 21, 2026, 6:29 AM EDT
Terminated Phase 3 Interventional Results available

Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)

NCT00215943
View directory record Official record
Conditions
Multiple Myeloma
Interventions
zoledronic acid, dexamethasone, thalidomide, vincristine, adriamycin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
4
States / cities
Clearwater, Florida • Lakeland, Florida • Port Charlotte, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 21, 2026, 6:29 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers Results available

Opioid-Free Pain Protocol After Shoulder Arthroplasty

NCT05488847
View directory record Official record
Conditions
Shoulder Arthropathy, Shoulder Pain
Interventions
Celecoxib, Pregabalin, Tramadol, Dexamethasone, Acetaminophen, Ropivicaine, Epinephrine, Ketorolac, Tizanidine, Magnesium, Ibuprofen, Oxycodone Hydrochloride 5 Mg
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 21, 2026, 6:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Using Dexamethasone After Uvulopalatopharyngoplasty

NCT00584168
View directory record Official record
Conditions
Pain
Interventions
Dexamethasone, Placebo
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 21, 2026, 6:29 AM EDT
Completed Not applicable Interventional

Pre-Emptive Analgesia in Ano-Rectal Surgery

NCT02402543
View directory record Official record
Conditions
Hemorrhoids, Fissure in Ano, Rectal Fistula, Anal Condyloma
Interventions
Gabapentin, Ketamine, Acetaminophen, Dexamethasone, Placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Burlington, Vermont • Colchester, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 21, 2026, 6:29 AM EDT
Withdrawn Phase 2 Interventional

Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy

NCT04223661
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide Pill, Dexamethasone, Daratumumab
Drug
Lead sponsor
Attaya Suvannasankha
Other
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 21, 2026, 6:29 AM EDT
Recruiting Phase 1 Interventional

Dexamethasone Use in Pediatric Rhabdomyolysis Patients in Addition to Standard Protocols

NCT06429982
View directory record Official record
Conditions
Rhabdomyolysis
Interventions
Dexamethasone, Placebo
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
6 Months to 25 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 21, 2026, 6:29 AM EDT
Completed Phase 3 Interventional Results available

Use of Dexamethasone in Pediatric Asthma Exacerbations

NCT02192827
View directory record Official record
Conditions
Asthma
Interventions
Dexamethasone Sodium Phosphate Injection
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
2 Years to 20 Years
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 21, 2026, 6:29 AM EDT
Recruiting Early Phase 1 Interventional

Does Nerve Block + Oral Dexamethasone Reduce Recurrence of Headache Within 72 Hrs?

NCT06016465
View directory record Official record
Conditions
Migraine
Interventions
Dexamethasone Oral, Placebo
Drug
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 85 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 21, 2026, 6:29 AM EDT
Completed Phase 2 Interventional Results available

Dexamethasone Dyspnea Study

NCT01670097
View directory record Official record
Conditions
Advanced Cancers, Hematologic Disorder, Solid Tumors
Interventions
Dexamethasone, Placebo, Questionnaires, Spirometer, Phone Calls
Drug · Behavioral · Device + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 21, 2026, 6:29 AM EDT
Active, not recruiting Early Phase 1 Interventional

A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

NCT05560399
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Iberdomide, Elotuzumab, Dexamethasone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 21, 2026, 6:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Alcohol and Gender Effects on Stress Circuit Function

NCT00226694
View directory record Official record
Conditions
Alcoholism, Stress, Alcohol Dependence
Interventions
Citalopram, Placebo
Drug · Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Oct 21, 2026, 6:29 AM EDT
Recruiting Phase 2 Interventional

Outpatient Epcoritamab in Large B-cell Lymphoma

NCT06811272
View directory record Official record
Conditions
Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma
Interventions
Epcoritamab, Rituximab combined with cyclophosphamide, vincristine, and prednisone, Rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone, Rituximab combined with polatuzumab, cyclophosphamide, doxorubicin, and prednisone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 21, 2026, 6:29 AM EDT
Withdrawn Phase 2 Interventional

Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT00836173
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
RICE, GaRD Treatment
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Oct 21, 2026, 6:29 AM EDT
Not listed Phase 1Phase 2 Interventional

Status Migrainosus - Differentiating Between Responders and Non-responders

NCT03066544
View directory record Official record
Conditions
Migraine
Interventions
Bupivacaine, Naratriptan Pill, Dexamethasone, Ketorolac
Drug
Lead sponsor
Hartford HealthCare
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Wethersfield, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 21, 2026, 6:29 AM EDT
Completed Phase 2 Interventional Results available

Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger

NCT00290498
View directory record Official record
Conditions
Lymphoma
Interventions
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Dexamethasone, Methotrexate, Cytarabine, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years to 60 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Oct 21, 2026, 6:29 AM EDT
Active, not recruiting Phase 3 Interventional

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

NCT00572169
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Velcade, Thalidomide, Dexamethasone, Adriamycin, Cisplatin, Cyclophosphamide, Etoposide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 21, 2026, 6:29 AM EDT
Recruiting Phase 2 Interventional

Assessment of Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients

NCT06780202
View directory record Official record
Conditions
Foot Injuries and Disorders, Ankle Injuries and Disorders, Achilles Tendon Injury
Interventions
medrol dosepak, HYDROcodone Oral Tablet
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 95 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia • Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 21, 2026, 6:29 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

The Efficacy of Liposomal Bupivacaine in Ultrasound Guided Supraclavicular Nerve Blocks for Hand and Wrist Surgery

NCT06806410
View directory record Official record
Conditions
Hand Surgery, Wrist Surgery, Elbow Surgery, Fracture Fixation, Dupuytren Contracture, Finger Fracture, Wrist Arthropathy, Distal Radius Fracture
Interventions
Liposomal bupivacaine (LB), Dexamethasone
Drug
Lead sponsor
St. Luke's Hospital, Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 21, 2026, 6:29 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

NCT05911321
View directory record Official record
Conditions
Multiple Myeloma, Relapse, Refractory, Aging, Co-morbidity
Interventions
Isatuximab, Pomalidomide, Dexamethasone
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 21, 2026, 6:29 AM EDT
Completed Phase 4 Interventional Results available

ACL Repair and Multimodal Analgesia

NCT01868425
View directory record Official record
Conditions
Pain
Interventions
multimodal:acetaminophen, gabapentin, ketamine, bupivacaine, placebo pills and injectables
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 55 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 21, 2026, 6:29 AM EDT